Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cells

被引:142
作者
Zhao, Yong [1 ]
Jiang, Zhaoshun [2 ]
Zhao, Tingbao [3 ]
Ye, Mingliang [4 ]
Hu, Chengjin [5 ]
Yin, Zhaohui [2 ]
Li, Heng [6 ]
Zhang, Ye [4 ,7 ]
Diao, Yalin [4 ]
Li, Yunxiang
Chen, Yingjian [5 ]
Sun, Xiaoming [5 ]
Fisk, Mary Beth [8 ]
Skidgel, Randal [9 ]
Holterman, Mark [10 ]
Prabhakar, Bellur [11 ]
Mazzone, Theodore [1 ]
机构
[1] Univ Illinois, Dept Med, Sect Endocrinol Diabet & Metab, Chicago, IL 60612 USA
[2] Gen Hosp Jinan Mil Command, Endocrinol Sect, Jinan 250031, Shandong, Peoples R China
[3] Gen Hosp Jinan Mil Command, Stem Cell Treatment Ctr, Jinan 250031, Shandong, Peoples R China
[4] Gen Hosp Jinan Mil Command, Sect Blood Transfus, Jinan 250031, Shandong, Peoples R China
[5] Gen Hosp Jinan Mil Command, Sect Mol Diagnost, Jinan 250031, Shandong, Peoples R China
[6] Jinan Cent Hosp, Sect Neuronol, Jinan 250020, Shandong, Peoples R China
[7] Jinan Tianhe Stem Cell Biotechol Co Ltd, Jinan 250055, Shandong, Peoples R China
[8] Texas Cord Blood Bank, San Antonio, TX 78201 USA
[9] Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA
[10] Univ Illinois, Dept Surg, Peoria, IL 61603 USA
[11] Univ Illinois, Dept Immunol & Microbiol, Chicago, IL 60612 USA
关键词
REGULATORY T-CELLS; CUTTING EDGE; DOUBLE-BLIND; C-REL; TOLERANCE; THERAPY; CD28; GAD; MECHANISMS; UNIQUE;
D O I
10.1186/1741-7015-10-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Inability to control autoimmunity is the primary barrier to developing a cure for type 1 diabetes (T1D). Evidence that human cord blood-derived multipotent stem cells (CB-SCs) can control autoimmune responses by altering regulatory T cells (Tregs) and human islet beta cell-specific T cell clones offers promise for a new approach to overcome the autoimmunity underlying T1D. Methods: We developed a procedure for Stem Cell Educator therapy in which a patient's blood is circulated through a closed-loop system that separates lymphocytes from the whole blood and briefly co-cultures them with adherent CB-SCs before returning them to the patient's circulation. In an open-label, phase1/phase 2 study, patients (n = 15) with T1D received one treatment with the Stem Cell Educator. Median age was 29 years (range: 15 to 41), and median diabetic history was 8 years (range: 1 to 21). Results: Stem Cell Educator therapy was well tolerated in all participants with minimal pain from two venipunctures and no adverse events. Stem Cell Educator therapy can markedly improve C-peptide levels, reduce the median glycated hemoglobin A1C (HbA1C) values, and decrease the median daily dose of insulin in patients with some residual beta cell function (n = 6) and patients with no residual pancreatic islet beta cell function (n = 6). Treatment also produced an increase in basal and glucose-stimulated C-peptide levels through 40 weeks. However, participants in the Control Group (n = 3) did not exhibit significant change at any follow-up. Individuals who received Stem Cell Educator therapy exhibited increased expression of co-stimulating molecules (specifically, CD28 and ICOS), increases in the number of CD4(+)CD25(+)Foxp3(+) Tregs, and restoration of Th1/Th2/Th3 cytokine balance. Conclusions: Stem Cell Educator therapy is safe, and in individuals with moderate or severe T1D, a single treatment produces lasting improvement in metabolic control. Initial results indicate Stem Cell Educator therapy reverses autoimmunity and promotes regeneration of islet beta cells. Successful immune modulation by CB-SCs and the resulting clinical improvement in patient status may have important implications for other autoimmune and inflammation-related diseases without the safety and ethical concerns associated with conventional stem cell-based approaches.
引用
收藏
页数:11
相关论文
共 42 条
[1]   Immunomodulation by mesenchymal stem cells - A potential therapeutic strategy for type 1 diabetes [J].
Abdi, Reza ;
Fiorina, Paolo ;
Adra, Chaker N. ;
Atkinson, Mark ;
Sayegh, Mohamed H. .
DIABETES, 2008, 57 (07) :1759-1767
[2]   Stem cell therapy for type 1 diabetes mellitus [J].
Aguayo-Mazzucato, Cristina ;
Bonner-Weir, Susan .
NATURE REVIEWS ENDOCRINOLOGY, 2010, 6 (03) :139-148
[3]   How Does Type 1 Diabetes Develop? The Notion of Homicide or β-Cell Suicide Revisited [J].
Atkinson, Mark A. ;
Bluestone, Jeffrey A. ;
Eisenbarth, George S. ;
Hebrok, Matthias ;
Herold, Kevan C. ;
Accili, Domenico ;
Pietropaolo, Massimo ;
Arvan, Peter R. ;
Von Herrath, Matthias ;
Markel, Dorene S. ;
Rhodes, Christopher J. .
DIABETES, 2011, 60 (05) :1370-1379
[4]   Anti-CD3 antibodies for type 1 diabetes: beyond expectations [J].
Bach, Jean-Francois .
LANCET, 2011, 378 (9790) :459-460
[5]   Genetics, pathogenesis and clinical interventions in type 1 diabetes [J].
Bluestone, Jeffrey A. ;
Herold, Kevan ;
Eisenbarth, George .
NATURE, 2010, 464 (7293) :1293-1300
[6]   T Regulatory Cells in Autoimmune Diabetes: Past Challenges, Future Prospects [J].
Bluestone, Jeffrey A. ;
Tang, Qizhi ;
Sedwick, Caitlin E. .
JOURNAL OF CLINICAL IMMUNOLOGY, 2008, 28 (06) :677-684
[7]   Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family [J].
Bour-Jordan, Helene ;
Esensten, Jonathan H. ;
Martinez-Llordella, Marc ;
Penaranda, Cristina ;
Stumpf, Melanie ;
Bluestone, Jeffrey A. .
IMMUNOLOGICAL REVIEWS, 2011, 241 :180-205
[9]   Pancreatic β-Cell Neogenesis by Direct Conversion from Mature α-Cells [J].
Chung, Cheng-Ho ;
Hao, Ergeng ;
Piran, Ron ;
Keinan, Ehud ;
Levine, Fred .
STEM CELLS, 2010, 28 (09) :1630-1638
[10]   CLINICAL STUDIES Trying to Reset the Clock On Type 1 Diabetes [J].
Couzin-Frankel, Jennifer .
SCIENCE, 2011, 333 (6044) :819-821